Mineralys Therapeutics, Inc.
MLYS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $15 | $0 | $0 | $0 |
| Gross Profit | -$15 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $31,450 | $38,278 | $37,879 | $44,569 |
| G&A Expenses | $9,681 | $8,468 | $6,568 | $7,198 |
| SG&A Expenses | $9,681 | $8,468 | $6,568 | $7,198 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $41,116 | $46,746 | $44,447 | $51,767 |
| Operating Income | -$41,131 | -$46,746 | -$44,447 | -$51,767 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $4,199 | $3,472 | $2,236 | $2,821 |
| Pre-Tax Income | -$36,932 | -$43,274 | -$42,211 | -$48,946 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$36,932 | -$43,274 | -$42,211 | -$48,946 |
| % Margin | – | – | – | – |
| EPS | -0.52 | -0.66 | -0.79 | -0.98 |
| % Growth | 21.2% | 16.5% | 19.4% | – |
| EPS Diluted | -0.52 | -0.66 | -0.79 | -0.98 |
| Weighted Avg Shares Out | 70,595 | 65,451 | 53,163 | 49,957 |
| Weighted Avg Shares Out Dil | 70,595 | 65,451 | 53,164 | 49,958 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4,195 | $3,474 | $2,239 | $2,809 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $15 | $16 | $15 | $15 |
| EBITDA | -$36,917 | -$46,730 | -$44,432 | -$51,752 |
| % Margin | – | – | – | – |